The estimated Net Worth of David W Anstice is at least 2.62 百万$ dollars as of 14 June 2022. Mr. Anstice owns over 7,585 units of Alkermes plc stock worth over 2,255,926$ and over the last 13 years he sold ALKS stock worth over 0$. In addition, he makes 366,236$ as Lead Independent Director at Alkermes plc.
David has made over 9 trades of the Alkermes plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 7,585 units of ALKS stock worth 201,533$ on 14 June 2022.
The largest trade he's ever made was exercising 40,000 units of Alkermes plc stock on 13 December 2017 worth over 457,600$. On average, David trades about 5,876 units every 104 days since 2011. As of 14 June 2022 he still owns at least 84,905 units of Alkermes plc stock.
You can see the complete history of Mr. Anstice stock trades at the bottom of the page.
David W. Anstice serves as Lead Independent Director of the Company. Mr. Anstice served as Executive Vice President of Merck & Co., Inc. (“Merck”) from 2006 until his retirement in 2008, with responsibility for enterprise strategy and implementation. During separate parts of this period he served as acting President, Global Human Health and as President of Merck’s business in Japan. Prior to that, Mr. Anstice served as President of Merck from 2003 to 2006, with responsibility for Merck’s Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions including President, U.S. Human Health; President, Human Health, the Americas; President, U.S./Canada; and President, Human Health, Europe. He reported to the Chief Executive Officer of Merck from 1994 until his retirement in 2008. Mr. Anstice currently serves as a non-executive director of NeuClone Pharmaceuticals Ltd., an unlisted clinical-stage biopharmaceutical company based in Australia. Mr. Anstice previously served as a non-executive director of CSL Limited, a global biopharmaceutical company, from September 2008 until October 2018. Mr. Anstice is also Chairman and President of the board for the University of Sydney USA Foundation, and an Adjunct Professor at the University of Sydney Business School.
As the Lead Independent Director of Alkermes plc, the total compensation of David Anstice at Alkermes plc is 366,236$. There are 13 executives at Alkermes plc getting paid more, with Richard Pops having the highest compensation of 14,637,100$.
David Anstice is 70, he's been the Lead Independent Director of Alkermes plc since 2019. There are 3 older and 18 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.
David's mailing address filed with the SEC is Connaught House, Burlington Rd, Dublin 4, Ireland.
Over the last 13 years, insiders at Alkermes plc have traded over 407,046,771$ worth of Alkermes plc stock and bought 86,119 units worth 2,034,840$ . The most active insiders traders include Corp Plc Elan Science Three...、Richard F Pops、James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of 1,083,232$. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth 53,512$.
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Alkermes plc executives and other stock owners filed with the SEC include: